Comments

Arcturus Therapeutics

ARCTNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$24.21
0.421.77%
Last update: 9:30 AM
15 minutes delayed
Q2 2024 Earnings in 14 days from now on Mon Aug 5th, after the market close
Arcturus Therapeutics (ARCT) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$86.00
Lowest Price Target1
$14.00
Consensus Price Target1
$51.50

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Arcturus Therapeutics (NASDAQ:ARCT) Stock, Analyst Ratings, Price Targets, Forecasts

Arcturus Therapeutics Holdings Inc has a consensus price target of $51.5 based on the ratings of 14 analysts. The high is $86 issued by Canaccord Genuity on May 10, 2024. The low is $14 issued by Goldman Sachs on November 10, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co. on July 2, 2024, May 10, 2024, and March 20, 2024, respectively. With an average price target of $68.67 between HC Wainwright & Co., Canaccord Genuity, and HC Wainwright & Co., there's an implied 191.76% upside for Arcturus Therapeutics Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
1
Mar
0
0
0
0
May
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Canaccord Genuity
HC Wainwright & Co.
Wells Fargo
Citigroup

1calculated from analyst ratings

Analyst Ratings for Arcturus Therapeutics

Buy NowGet Alert
07/02/2024Buy Now154.94%HC Wainwright & Co.
Ed Arce
$60 → $60ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now265.41%Canaccord Genuity
Whitney Ijem
$87 → $86MaintainsBuyGet Alert
03/20/2024Buy Now154.94%HC Wainwright & Co.— → $60ReiteratesBuy → BuyGet Alert
03/11/2024Buy Now269.66%Canaccord Genuity
Whitney Ijem
$81 → $87MaintainsBuyGet Alert
03/08/2024Buy Now154.94%HC Wainwright & Co.
Ed Arce
 → $60ReiteratesBuy → BuyGet Alert
03/08/2024Buy Now146.44%Wells Fargo
John Abbott
$45 → $58MaintainsOverweightGet Alert
02/08/2024Buy Now103.95%Citigroup
Yigal Nochomovitz
$40 → $48MaintainsBuyGet Alert
12/13/2023Buy Now—Canaccord Genuity
Whitney Ijem
—Initiates → BuyGet Alert
11/28/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
11/15/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
09/27/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
09/20/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
09/05/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
08/22/2023Buy Now129.45%Cantor Fitzgerald
Pete Stavropoulos
 → $54ReiteratesOverweight → OverweightGet Alert
08/15/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
07/24/2023Buy Now201.68%William Blair
Myles Minter
 → $71Initiates → OutperformGet Alert
07/14/2023Buy Now—Guggenheim
Seamus Fernandez
—MaintainsBuyGet Alert
07/14/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51ReiteratesBuy → BuyGet Alert
07/14/2023Buy Now129.45%Cantor Fitzgerald
Pete Stavropoulos
 → $54ReiteratesOverweight → OverweightGet Alert
06/01/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51Reiterates → BuyGet Alert
05/11/2023Buy Now116.7%HC Wainwright & Co.
Ed Arce
 → $51UpgradeNeutral → BuyGet Alert
03/29/2023Buy Now52.96%Guggenheim
Seamus Fernandez
 → $36Reiterates → BuyGet Alert
03/29/2023Buy Now-19.27%HC Wainwright & Co.
Ed Arce
 → $19Reiterates → NeutralGet Alert
11/10/2022Buy Now-40.51%Goldman Sachs
Madhu Kumar
$8 → $14MaintainsSellGet Alert
11/10/2022Buy Now-23.52%Baird
Joel Beatty
 → $18DowngradeNeutral → UnderperformGet Alert
11/03/2022Buy Now—Citigroup
Yigal Nochomovitz
—UpgradeNeutral → BuyGet Alert
11/02/2022Buy Now6.22%Barclays
Gena Wang
$16 → $25UpgradeUnderweight → Equal-WeightGet Alert
11/02/2022Buy Now86.96%Cantor Fitzgerald
Pete Stavropoulos
$39 → $44MaintainsOverweightGet Alert
08/10/2022Buy Now-32.02%Barclays
Gena Wang
$17 → $16MaintainsUnderweightGet Alert
08/10/2022Buy Now316.4%Wells Fargo
John Abbott
$105 → $98MaintainsOverweightGet Alert
08/10/2022Buy Now—Raymond James
Steven Seedhouse
—DowngradeMarket Perform → UnderperformGet Alert
07/19/2022Buy Now65.71%Cantor Fitzgerald
Pete Stravropoulos
 → $39Assumes → OverweightGet Alert
05/24/2022Buy Now-66.01%Goldman Sachs
Madhu Kumar
$14 → $8MaintainsSellGet Alert
05/11/2022Buy Now-40.51%Goldman Sachs
Madhu Kumar
$16 → $14MaintainsSellGet Alert
05/11/2022Buy Now-23.52%Baird
Joel Beatty
$21 → $18UpgradeUnderperform → NeutralGet Alert
05/10/2022Buy Now-27.77%Barclays
Gena Wang
$21 → $17MaintainsUnderweightGet Alert
05/10/2022Buy Now-19.27%HC Wainwright & Co.
Ed Arce
$25 → $19MaintainsNeutralGet Alert
03/25/2022Buy Now346.14%Wells Fargo
John Abbott
$107 → $105MaintainsOverweightGet Alert
03/15/2022Buy Now265.41%Citigroup
Yigal Nochomovitz
$114 → $86MaintainsBuyGet Alert
03/01/2022Buy Now354.64%Wells Fargo
John Abbott
$118 → $107MaintainsOverweightGet Alert
01/31/2022Buy Now—Raymond James
Steven Seedhouse
—UpgradeUnderperform → Market PerformGet Alert
11/09/2021Buy Now31.72%Barclays
Gena Wang
—MaintainsUnderweightGet Alert
08/25/2021Buy Now384.38%Citigroup
Yigal Nochomovitz
—MaintainsBuyGet Alert
08/12/2021Buy Now—Raymond James
Steven Seedhouse
—DowngradeMarket Perform → UnderperformGet Alert
08/11/2021Buy Now23.22%Goldman Sachs
Madhu Kumar
—DowngradeNeutral → SellGet Alert
08/10/2021Buy Now261.16%Cantor Fitzgerald
Brian Cheng
—MaintainsOverweightGet Alert
08/10/2021Buy Now—Baird
Joel Beatty
—DowngradeNeutral → UnderperformGet Alert

FAQ

Q

What is the target price for Arcturus Therapeutics (ARCT) stock?

A

The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by HC Wainwright & Co. on July 2, 2024. The analyst firm set a price target for $60.00 expecting ARCT to rise to within 12 months (a possible 147.83% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arcturus Therapeutics (ARCT)?

A

The latest analyst rating for Arcturus Therapeutics (NASDAQ:ARCT) was provided by HC Wainwright & Co., and Arcturus Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Arcturus Therapeutics (ARCT)?

A

The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.

Q

When was the last downgrade for Arcturus Therapeutics (ARCT)?

A

The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for Arcturus Therapeutics (ARCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.

Q

Is the Analyst Rating Arcturus Therapeutics (ARCT) correct?

A

While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a reiterated with a price target of $60.00 to $60.00. The current price Arcturus Therapeutics (ARCT) is trading at is $24.21, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch